We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lack of Autoantibodies Against Related Proteins in Collagenous Colitis

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: Histological features of collagenous colitis (Photo courtesy of Michael Bonert, MD, FRCPC)
Image: Histological features of collagenous colitis (Photo courtesy of Michael Bonert, MD, FRCPC)

Collagenous colitis (CC) is an inflammatory disorder in the colonic mucosa that predominantly affects elderly women and causes chronic, non-bloody diarrhea with normal or close to normal endoscopic findings.

The histological criteria for CC are a thickened sub-epithelial collagen layer (> 10 µm) in the extracellular matrix (ECM) of the mucosa, epithelial damage and presence of an inflammatory infiltrate in the lamina propria. CC shares many of the characteristics found in autoimmune diseases, but no autoantibodies have been identified. In CC, an imbalance in collagen turnover is evident.

Gastroenterologists at the Skåne University Hospital (Malmö, Sweden) included in a study, 66 women with CC. The mean age at inclusion was 60 years (range 31–74 years) and mean age at diagnosis was 55 years (range 28–69 years). The size of the control groups differed, but they were selected from the same cohort consisting of 100 healthy female blood donors. The mean age of the total control group was 41.7 years (range 19–69).

In-house enzyme-linked immunosorbent assays (ELISAs) were set up for analysis of anti-IgM and IgG antibodies against collagen type III (Col III and IV). Analyses of antibodies against matrix metalloproteinase-9 (MMP-9 and Tenascin-C (TNC) were conducted by in-house ELISAs and another in-house ELISA was set up for analysis of IgM and IgG antibodies against tissue inhibitors of metalloproteinase (TIMP-1). Anti-Saccharomyces cerevisiae antibodies (ASCA) IgG were analyzed by a fluorescent enzyme immunoassay method (FEIA) for which the reference value is set > 10 U/mL (Orgentec Diagnostika, Mainz, Germany). Thyroid peroxidase (TPO) antibodies were analyzed by a chemiluminescence enzyme immunological method (Siemens Healthcare GmbH, Erlangen, Germany).

The investigators reported that there was no difference in prevalence of these collage-associated autoantibodies between CC patients and controls. Sixteen patients expressed one type of autoantibody, whereas two patients expressed two different types. The mean disease duration was significantly lower in the subjects who expressed collagen-associated autoantibodies (3.7 years; range 1–14), compared to those who did not (6.4 years; range 1–22). The presence of autoantibodies against TPO and ASCA was slightly increased compared to controls, but not statistically significant. Increased levels of total IgE were equally present in the CC patients and the control group, and there was no correlation between total IgE-positivity and presence of any autoantibodies.

The authors concluded that no increased presence of the investigated antibodies could be found in the present study of CC. Neither could antibodies against ASCA or TPO, or elevated levels of IgE, be found. Consequently, no association was found between CC and these proteins, even though this may not be generalizable to other compounds in the collagen layer. The study was published on June 6, 2022 in the journal BMC Immunology.

Related Links:
Skåne University Hospital 
Orgentec Diagnostika 
Siemens Healthcare GmbH 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
High Performance Centrifuge
CO336/336R

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.